Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications

This article was originally published here

“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion to develop SENS-401 for

The post Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply